LivaNova (NASDAQ:LIVN) Upgraded to Strong-Buy at StockNews.com

StockNews.com upgraded shares of LivaNova (NASDAQ:LIVN) from a buy rating to a strong-buy rating in a research note published on Tuesday morning.

Several other analysts have also recently commented on LIVN. Needham & Company LLC reiterated a “buy” rating and issued a $64.00 price target on shares of LivaNova in a research report on Monday, March 17th. Mizuho decreased their target price on shares of LivaNova from $70.00 to $60.00 and set an “outperform” rating for the company in a research report on Wednesday, February 26th. Wolfe Research lowered shares of LivaNova from an “outperform” rating to a “peer perform” rating in a research note on Wednesday, February 26th. Stifel Nicolaus decreased their price objective on shares of LivaNova from $72.00 to $60.00 and set a “buy” rating on the stock in a report on Wednesday, February 26th. Finally, Barclays lowered their price objective on LivaNova from $58.00 to $56.00 and set an “equal weight” rating on the stock in a research report on Friday, March 7th. Two investment analysts have rated the stock with a hold rating, five have issued a buy rating and two have issued a strong buy rating to the stock. According to MarketBeat.com, LivaNova currently has a consensus rating of “Buy” and a consensus target price of $61.17.

LivaNova Stock Performance

LivaNova stock opened at $39.92 on Tuesday. The firm has a market capitalization of $2.17 billion, a P/E ratio of 95.05 and a beta of 1.10. The stock has a fifty day moving average price of $45.01 and a two-hundred day moving average price of $48.65. The company has a debt-to-equity ratio of 0.46, a current ratio of 3.37 and a quick ratio of 2.87. LivaNova has a 52-week low of $36.85 and a 52-week high of $64.48.

Institutional Investors Weigh In On LivaNova

Several hedge funds have recently added to or reduced their stakes in LIVN. Intech Investment Management LLC lifted its holdings in shares of LivaNova by 80.4% during the third quarter. Intech Investment Management LLC now owns 15,815 shares of the company’s stock valued at $831,000 after purchasing an additional 7,049 shares during the last quarter. Charles Schwab Investment Management Inc. grew its position in LivaNova by 17.7% in the 3rd quarter. Charles Schwab Investment Management Inc. now owns 621,959 shares of the company’s stock worth $32,678,000 after purchasing an additional 93,311 shares during the period. Cerity Partners LLC purchased a new stake in LivaNova during the third quarter valued at $573,000. The Manufacturers Life Insurance Company increased its holdings in LivaNova by 286.4% during the third quarter. The Manufacturers Life Insurance Company now owns 207,248 shares of the company’s stock valued at $10,889,000 after buying an additional 153,611 shares during the last quarter. Finally, Quantbot Technologies LP purchased a new position in LivaNova during the third quarter valued at $1,984,000. Institutional investors own 97.64% of the company’s stock.

About LivaNova

LivaNova PLC, a medical device company, designs, develops, manufactures, and sells therapeutic solutions worldwide. The company operates through Cardiopulmonary, Neuromodulation, and Advanced Circulatory Support segments. The Cardiopulmonary segment develops, produces, and sells cardiopulmonary products, including oxygenators, heart-lung machines, autotransfusion systems, perfusion tubing systems, cannulae, connect, and other related products.